Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...
Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their ...
Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
In recent years, the familiar symptoms of the flu might kick us into reaching for at-home testing kits. But on the eve of the ...
The risk for new-onset or recurrent AF was not increased among older adult patients with preexisting conditions following RSV vaccination.
England’s RSV vaccination programme has achieved a 30% reduction in RSV-related hospital admissions among older adults.
The Allan Labor Government is keeping Victorian babies safe from Respiratory Syncytial Virus (RSV) this winter, with a long-acting immunisation ...
Early data suggests that the respiratory syncytial virus (RSV) vaccination programme is significantly reducing hospital admissions among ...
Starting this spring, the Respiratory Syncytial Virus (RSV) vaccine will be available to adults aged 60 years and older residing in congregate living facilities, such as long-term care homes and ...